Overview

Cyclobenzaprine HCl Extended Release 15 mg Versus Placebo in Treatment of Cervical and/or Lower Back Pain Due to Muscle Spasms of Local Origin

Status:
Completed

Trial end date:
2017-03-14

Target enrollment:

Participant gender:

Summary

The purpose of this study was to assess the effect of cyclobenzaprine hydrochloride (HCl) extended release (CER) 15 mg capsule once daily in participants with muscle spasms associated with acute painful musculoskeletal conditions.

Phase:

Phase 3

Details

Lead Sponsor:

Takeda

Treatments:

Amitriptyline
Cyclobenzaprine